Clinical trial · Interventional
Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer
NCT06772935CI-TRIAL-00084646CIPNrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Electro-acupuncture | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Electroacupuncture+Routine Nursing Group
- interventionNames
- Behavioral: Electro-acupuncture
- type
- PLACEBO_COMPARATOR
- label
- Fake electroacupuncture + Routine Nursing Group
- interventionNames
- Behavioral: Electro-acupuncture
Primary outcomes (1)
- measure
- Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity Index （FACT/GOG-NTX）
- timeFrame
- After enrollment, the first assessment of the scale will be conducted, followed by another assessment of the scale at the 4th and 8th week of treatment (7 days per week).
- description
- This scale is mainly used to evaluate chemotherapy induced peripheral neuropathy (CIPN), especially the neurotoxic reactions in gynecological tumor treatment. Through this scale, it is possible to quantify the neurotoxic symptoms that patients experience after receiving chemotherapy, such as sensory abnormalities, motor dysfunction, etc., in order to better monitor and manage the patient's health status.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria:
* Breast cancer patients diagnosed by pathology;
* EOOG score is 0 or 1;
* The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);
⑤ Previously received taxane chemotherapy for more than 6 months;
⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;
⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
* Accept regular follow-up visits; ⑨ There is complete pathological data available.
Exclusion Criteria:
* Non breast cancer patients;
* Received electroacupuncture treatment within 6 months prior to the start of the study;
* Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;
* Prior to enrollment, there was a history of peripheral neuropathy;
* Unstable heart disease or myocardial infarction within the first 6 months of the study;
⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;
⑦ Uncontrolled epilepsy patients with uncontrolled seizures;
⑧ Merge with other malignant tumor patients;
⑨ Pregnancy and lactation period;
⑩ Refusal to join clinical trial patientsReferences
Publications (0)
Data not yet available
No reference posted for this study.